相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
Alex A. Adjei et al.
INVESTIGATIONAL NEW DRUGS (2017)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Jean-Luc Van Laethem et al.
TARGETED ONCOLOGY (2017)
Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs
Ryan H. Takahashi et al.
XENOBIOTICA (2017)
MEK inhibitors in oncology: a patent review (2015-Present)
Debarshi Kar Mahapatra et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
Anuradha Krishnamurthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
David R. Gandara et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2017)
LGG-08. A PHASE II PROSPECTIVE STUDY OF SELUMETINIB IN CHILDREN WITH RECURRENT OR REFRACTORY LOW-GRADE GLIOMA (LGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
Jason Fangusaro et al.
NEURO-ONCOLOGY (2017)
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee et al.
NEURO-ONCOLOGY (2017)
Atezolizumab (A) plus cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
Wilson H. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors
Antonio M. Grimaldi et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C. Bendell et al.
BRITISH JOURNAL OF CANCER (2017)
Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells
Wei Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
Ester Simeone et al.
BIODRUGS (2017)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs et al.
BIOMARKER RESEARCH (2017)
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
W. M. Tai et al.
ANNALS OF ONCOLOGY (2016)
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
David Jamieson et al.
EUROPEAN JOURNAL OF CANCER (2016)
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
Lee S. Rosen et al.
INVESTIGATIONAL NEW DRUGS (2016)
Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent
Jessica T. Leonard et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Emerging therapeutic agents for lung cancer
Bhagirathbhai Dholaria et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Novel melanoma therapy
Eddy C. Hsueh et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Paola Queirolo et al.
CANCER TREATMENT REVIEWS (2015)
MEK inhibitors beyond monotherapy: current and future development
Ian E. Templeton et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Juliet Richman et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Nivolumab plus ipilimumab in the treatment of advanced melanoma
Katy K. Tsai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)
J. El-Hoss et al.
BONE (2014)
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Nitin Jain et al.
CLINICAL CANCER RESEARCH (2014)
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Ho Yeong Lim et al.
CLINICAL CANCER RESEARCH (2014)
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2014)
Prospects for MEK inhibitors for treating cancer
Juan Martin-Liberal et al.
EXPERT OPINION ON DRUG SAFETY (2014)
BRAF inhibitors in cancer therapy
Carolina Hertzman Johansson et al.
PHARMACOLOGY & THERAPEUTICS (2014)
MEK in cancer and cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro
Emanuel Haasbach et al.
ANTIVIRAL RESEARCH (2013)
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
M. Beloueche-Babari et al.
BRITISH JOURNAL OF CANCER (2013)
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
Edna F. Choo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo
Dong Joon Kim et al.
CARCINOGENESIS (2013)
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
Roger B. Cohen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
Brigette B. Y. Ma et al.
INVESTIGATIONAL NEW DRUGS (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Georgia Hatzivassiliou et al.
NATURE (2013)
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Suzanne Leijen et al.
CLINICAL CANCER RESEARCH (2012)
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Maria Martinez-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623
E. Choo et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
A. Naing et al.
EUROPEAN JOURNAL OF CANCER (2012)
Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma
J. P. Delord et al.
EUROPEAN JOURNAL OF CANCER (2012)
Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
A. Awada et al.
EUROPEAN JOURNAL OF CANCER (2012)
Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors
N. Houede et al.
EUROPEAN JOURNAL OF CANCER (2012)
Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials
Francoise Kraeber-Bodere et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante et al.
LANCET ONCOLOGY (2012)
Mitogen-activated protein kinase in the amygdala plays a critical role in lithium chloride-induced taste aversion learning
Bumsup Kwon et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2012)
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
Kenneth D. Rice et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
Qing Dong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent
Yoshiaki Isshiki et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer
Peter D. Boasberg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
Hiroyuki Abe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
Gajanan S. Inamdar et al.
BIOCHEMICAL PHARMACOLOGY (2010)
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Eric B. Haura et al.
CLINICAL CANCER RESEARCH (2010)
Emerging MEK inhibitors
James A. McCubrey et al.
EXPERT OPINION ON EMERGING DRUGS (2010)
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression
Lucy Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
Hung Huynh et al.
JOURNAL OF HEPATOLOGY (2010)
Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
Sherif Daouti et al.
MOLECULAR CANCER THERAPEUTICS (2010)
PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice
Rosanna Di Paola et al.
PHARMACOLOGICAL RESEARCH (2010)
Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor
Edna F. Choo et al.
XENOBIOTICA (2010)
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
Cory Iverson et al.
CANCER RESEARCH (2009)
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Stephen D. Barrett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Putative allosteric MEK1 and MEK2 inhibitors
Steve Price
EXPERT OPINION ON THERAPEUTIC PATENTS (2008)
Clinical experience of MEK inhibitors in cancer therapy
Ding Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
Alan P. Brown et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer
Patrick J. Klein et al.
NEOPLASIA (2006)
Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors
SL Han et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
N Thompson et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway
K Dokladda et al.
FEBS LETTERS (2005)
In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human
PA Wabnitz et al.
PHARMACEUTICAL RESEARCH (2004)
Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP
HW Yung et al.
BIOCHEMICAL PHARMACOLOGY (2004)
The Raf/MEK inhibitor PD98059 enhances ERK1/2 phosphorylation mediated by peroxynitrite via enforced mitochondrial formation of reactive oxygen species
L Cerioni et al.
FEBS LETTERS (2003)
The ups and downs of MEK kinase interactions
C Hagemann et al.
CELLULAR SIGNALLING (2001)
Mammalian MAP kinase signalling cascades
LF Chang et al.
NATURE (2001)
分享论文
